164 related articles for article (PubMed ID: 38135836)
1. Learning Outcomes of "GetSMART," Education for Diagnostics and Targeted Treatment for HER2+ Metastatic Gastric and Colorectal Cancers.
Augustyniak M; Lou E; Jacobs G; Fleming M; Marshall J; Coutinho A; Yoshino T
J Cancer Educ; 2024 Apr; 39(2):118-125. PubMed ID: 38135836
[TBL] [Abstract][Full Text] [Related]
2. HER2 targeted therapy in colorectal Cancer: Current landscape and future directions.
Chen N; He L; Zou Q; Deng H
Biochem Pharmacol; 2024 May; 223():116101. PubMed ID: 38442793
[TBL] [Abstract][Full Text] [Related]
3. HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer.
Sartore-Bianchi A; Amatu A; Porcu L; Ghezzi S; Lonardi S; Leone F; Bergamo F; Fenocchio E; Martinelli E; Borelli B; Tosi F; Racca P; Valtorta E; Bonoldi E; Martino C; Vaghi C; Marrapese G; Ciardiello F; Zagonel V; Bardelli A; Trusolino L; Torri V; Marsoni S; Siena S
Oncologist; 2019 Oct; 24(10):1395-1402. PubMed ID: 30952821
[TBL] [Abstract][Full Text] [Related]
4. Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer.
Siena S; Sartore-Bianchi A; Marsoni S; Hurwitz HI; McCall SJ; Penault-Llorca F; Srock S; Bardelli A; Trusolino L
Ann Oncol; 2018 May; 29(5):1108-1119. PubMed ID: 29659677
[TBL] [Abstract][Full Text] [Related]
5. Human Epidermal Growth Factor Receptor 2-Targeting Approaches for Colorectal Cancer: Clinical Implications of Novel Treatments and Future Therapeutic Avenues.
Karan C; Tan E; Sarfraz H; Knepper TC; Walko CM; Felder S; Kim R; Sahin IH
JCO Oncol Pract; 2022 Aug; 18(8):545-554. PubMed ID: 35613416
[TBL] [Abstract][Full Text] [Related]
6. The effectiveness of internet-based e-learning on clinician behavior and patient outcomes: a systematic review protocol.
Sinclair P; Kable A; Levett-Jones T
JBI Database System Rev Implement Rep; 2015 Jan; 13(1):52-64. PubMed ID: 26447007
[TBL] [Abstract][Full Text] [Related]
7. Lgr5 over-expression is positively related to the tumor progression and HER2 expression in stage pTNM IV colorectal cancer.
Gao FJ; Chen JY; Wu HY; Shi J; Chen M; Fan XS; Huang Q
Int J Clin Exp Pathol; 2014; 7(4):1572-9. PubMed ID: 24817953
[TBL] [Abstract][Full Text] [Related]
8. Expression of EGFR, Her2 predict lymph node metastasis (LNM)-associated metastasis in colorectal cancer.
Lu Y; Jingyan G; Baorong S; Peng J; Xu Y; Cai S
Cancer Biomark; 2012; 11(5):219-26. PubMed ID: 23220854
[TBL] [Abstract][Full Text] [Related]
9. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study.
Meric-Bernstam F; Hurwitz H; Raghav KPS; McWilliams RR; Fakih M; VanderWalde A; Swanton C; Kurzrock R; Burris H; Sweeney C; Bose R; Spigel DR; Beattie MS; Blotner S; Stone A; Schulze K; Cuchelkar V; Hainsworth J
Lancet Oncol; 2019 Apr; 20(4):518-530. PubMed ID: 30857956
[TBL] [Abstract][Full Text] [Related]
10. Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.
Ross JS; Fakih M; Ali SM; Elvin JA; Schrock AB; Suh J; Vergilio JA; Ramkissoon S; Severson E; Daniel S; Fabrizio D; Frampton G; Sun J; Miller VA; Stephens PJ; Gay LM
Cancer; 2018 Apr; 124(7):1358-1373. PubMed ID: 29338072
[TBL] [Abstract][Full Text] [Related]
11. Mind the target: human epidermal growth factor receptor 2 in colorectal cancer.
Saúde-Conde R; Rasschaert G; Bregni G; Hendlisz A; Sclafani F
Curr Opin Oncol; 2022 Jul; 34(4):382-388. PubMed ID: 35730499
[TBL] [Abstract][Full Text] [Related]
12. HER2-specific chimeric antigen receptor-T cells for targeted therapy of metastatic colorectal cancer.
Xu J; Meng Q; Sun H; Zhang X; Yun J; Li B; Wu S; Li X; Yang H; Zhu H; Aschner M; Relucenti M; Familiari G; Chen R
Cell Death Dis; 2021 Nov; 12(12):1109. PubMed ID: 34839348
[TBL] [Abstract][Full Text] [Related]
13. Targeting ERBB2/HER2 genetic alterations: an expanding therapeutic opportunity in gastrointestinal cancers.
Zheng-Lin B; Graham RP; Bekaii-Saab TS
Chin Clin Oncol; 2023 Oct; 12(5):55. PubMed ID: 37964543
[TBL] [Abstract][Full Text] [Related]
14. Prospective analysis of the expression status of FGFR2 and HER2 in colorectal and gastric cancer populations: DS-Screen Study.
Yasui H; Takeno A; Hara H; Imamura H; Akamatsu H; Fujitani K; Nakane M; Kondoh CN; Yukisawa S; Nasu J; Miyata Y; Makiyama A; Ishida H; Yoshida N; Matsumura E; Ishigami M; Sugihara M; Ochiai A; Doi T
Int J Colorectal Dis; 2022 Jun; 37(6):1393-1402. PubMed ID: 35585358
[TBL] [Abstract][Full Text] [Related]
15. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.
Sartore-Bianchi A; Trusolino L; Martino C; Bencardino K; Lonardi S; Bergamo F; Zagonel V; Leone F; Depetris I; Martinelli E; Troiani T; Ciardiello F; Racca P; Bertotti A; Siravegna G; Torri V; Amatu A; Ghezzi S; Marrapese G; Palmeri L; Valtorta E; Cassingena A; Lauricella C; Vanzulli A; Regge D; Veronese S; Comoglio PM; Bardelli A; Marsoni S; Siena S
Lancet Oncol; 2016 Jun; 17(6):738-746. PubMed ID: 27108243
[TBL] [Abstract][Full Text] [Related]
16. Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer.
Kloth M; Ruesseler V; Engel C; Koenig K; Peifer M; Mariotti E; Kuenstlinger H; Florin A; Rommerscheidt-Fuss U; Koitzsch U; Wodtke C; Ueckeroth F; Holzapfel S; Aretz S; Propping P; Loeffler M; Merkelbach-Bruse S; Odenthal M; Friedrichs N; Heukamp LC; Zander T; Buettner R
Gut; 2016 Aug; 65(8):1296-305. PubMed ID: 26001389
[TBL] [Abstract][Full Text] [Related]
17. HER2: An emerging target in colorectal cancer.
Greally M; Kelly CM; Cercek A
Curr Probl Cancer; 2018 Nov; 42(6):560-571. PubMed ID: 30100092
[TBL] [Abstract][Full Text] [Related]
18. [Targeting HER2 in colorectal cancer].
Spitzer E; Cervera P; André T; Cohen R
Bull Cancer; 2023 Apr; 110(4):402-411. PubMed ID: 36870811
[TBL] [Abstract][Full Text] [Related]
19. HER2-targeted therapy: an emerging strategy in advanced colorectal cancer.
La Salvia A; Lopez-Gomez V; Garcia-Carbonero R
Expert Opin Investig Drugs; 2019 Jan; 28(1):29-38. PubMed ID: 30513002
[TBL] [Abstract][Full Text] [Related]
20. Complementary and Alternative Medicine Online Learning Intervention for Oncology Healthcare Providers: A Mixed-Methods Study.
Baydoun M; Levin G; Balneaves LG; Oberoi D; Sidhu A; Carlson LE
Integr Cancer Ther; 2022; 21():15347354221079280. PubMed ID: 35311375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
